UMB 425 is new drug for pain that has shown promising results in chronic pain, according to a new research. This research has been led by Andrew Coop, professor and chair of the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy .
The researchers have developed a new opioid drug which has shown great potential for advancement of the treatment and improvement in quality of life for people chronic pain.
The new drug is a compound called UMB 425 and it has been spotlighted in a recent issue of ACS Chemical Neuroscience.
The compound is as potent as morphine and lacks the tolerance or adverse effects of morphine. Tolerance is phenomenon in which the response of the body to drug decreases over the period when the drug is taken continuously and for eliciting the same response, higher amount of drug is needed.
UMB 425 is unique in mechanism. Unlike other drugs developed to act on only one biological target, UMB 425 mechanism acts two different opioid receptors in the body as compared to other drugs.
This leads to slow development of tolerance to the drug . This enables better responses with lower doses for longer periods.
Opioid drugs cause a number of side effects like constipation, nausea, drowsiness, and dizziness. When tolerance occurs and higher doses are being given, severity of side effects also increase.
This is where UMB 425 scores ahead of all other opioid drug because it acts on two receptors than one and patient can be treated with lower doses of the drug.
This would be a highly significant advance in pain management.
Drug is still being evaluated for getting optimal ratio at which it acts on the targeted opioid receptors so that pain relief is maximum and tolerance is minimum.
Chronic pain is a substantial health burden and new molecule would add to the arsenal of the clinician another molecule which could be used for treatment.
Get more stuff on Musculoskeltal Health
Subscribe to our Newsletter and get latest publications on Musculoskeletal Health your email inbox.
Thank you for subscribing.